Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Authors' conclusion
In our study of Asian patients, first-line lenvatinib treatment of metastatic or locally advanced, progressive, RAI-refractory DTC or PDTC was associated with a longer PFS compared with sorafenib. However, severe hypertension and proteinuria were observed more frequently after lenvatinib treatment than after sorafenib treatment.
Study context
- Population
- Patients with progressive distant metastatic or locally advanced, radioactive iodine (RAI)-refractory differentiated thyroid carcinoma (DTC) or poorly differentiated thyroid carcinoma (PDTC); median age 68 years, 35% male
- Participants
- 136 patients
- Exposure
- First-line lenvatinib vs sorafenib
- Lenvatinibn = 56
- Sorafenibn = 80reference
- Outcome
- Progression-free survival (PFS)
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
Median PFS
Hazard ratio
0.34
CI 0.19–0.60
P < 0.001
By group
Lenvatinibvs Sorafenib
HR 0.34 (CI 0.19–0.60); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
Partial response rate
P < 0.001
Safety
Grade 3-4 hypertension
P = 0.002
Grade 3-4 proteinuria
P < 0.001
Grade 3-4 hand-foot skin reaction
P = 0.001
Original publication
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study. Thyroid. Published 17 May 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →